[1]陈玉年,顾 兵,李华南,等.痛风性炎症自发性缓解的分子机制概述[J].中国药理学通报,2019,(10):1353-1356.[doi:10.3969/j.issn.1001-1978.2019.10.006]
 CHEN Yu-nian,GU Bing,LI Hua-nan,et al.Summary of molecular mechanisms of spontaneous remission in gouty inflammation[J].Chinese Pharmacological Bulletin,2019,(10):1353-1356.[doi:10.3969/j.issn.1001-1978.2019.10.006]





Summary of molecular mechanisms of spontaneous remission in gouty inflammation
陈玉年1顾 兵1李华南2余兆仲2
1.江西科技师范大学药学院,江西 南昌 330013; 2.江西中医药大学附属医院骨伤三科,江西 南昌 330006
CHEN Yu-nian1 GU Bing1 LI Hua-nan2 YU Zhao-zhong2
1.College of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China; 2.the third department of Orthopedics and Traumatology, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China
痛风 炎症反应 自发性缓解 分子机制 NLRP3炎症小体 内源性白细胞介素1受体拮抗剂 中性粒细胞胞外诱捕网
gout inflammatory reaction spontaneous remission molecular mechanism NLRP3 inflammasome intrinsic interleukin-1 receptor antagonist neutrophil extracellular traps
R331.123; R392.11; R392.12; R364.5; R589.7
急性痛风发作后会在一定时间内自行消退,这一过程称之为痛风性炎症的自发性缓解。其病理生理学机制与机体免疫系统中多种组分的动态调节有关,包括通过自身免疫细胞的吞噬,NLRP3炎症小体、白细胞介素1(interleukin 1,IL-1)和Toll样受体(Toll-like receptors,TLRs)等炎性介质的负调控,中性粒细胞胞外诱捕网(neutrophil extracellular traps,NETs)在晶体沉积部位的募集,以及局部慢性肉芽肿的形成等。该文就痛风性炎症自发性缓解的分子机制作一概述。
Acute gout subsides spontaneously within a certain period of time after onset, a process known as spontaneous remission of gouty inflammation.Its pathophysiological mechanism is related to the dynamic interaction of various components in the immune system, i.e.through the phagocytosis of autoimmune cells, the negative regulation of inflammatory mediators such as NLRP3 inflammasome, IL-1R and Toll-like receptors, the recruitment of neutrophil extracellular traps at the site of crystal deposition and the formation of local chronic granuloma, to alleviate the necrotizing inflammation mediated by monosodium urate crystals.This review summarizes the molecular mechanism of spontaneous remission of gouty inflammation.


[1] Dalbeth N, Merriman T R, Stamp L K.Gout[J].Lancet, 2016,388(10055):2039-52.
[2] Desai J, Steiger S, Anders H J.Molecular pathophysiology of gout[J].Trends Mol Med, 2017, 23(8): 756-68.
[3] Ragab G, Elshahaly M, Bardin T.Gout: an old disease in new perspective–a review[J].J Adv Res, 2017, 8(5): 495-511.
[4] Taylor W J, Fransen J, Jansen T L, et al.Study for updated gout classification criteria: identification of features to classify gout[J].Arthritis Care Res, 2015, 67(9): 1304-15.
[5] Scheti G, Schauer C, Hoffmann M, Herrmann M.Why does the gout attack stop? A roadmap for the immune pathogenesis of gout[J].RMD Open, 2015, 1(Suppl 1): e000046.
[6] Galli S J, Borregaard N, Wynn T A.Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils[J].Nat Immunol, 2011, 12(11): 1035-44.
[7] Martin W J, Shaw O, Liu X, et al.Monosodium urate monohydrate crystal–recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout[J].Arthritis Rheum, 2011, 63(5): 1322-32.
[8] Cumpelik A, Ankli B, Zecher D, et al.Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome[J].Ann Rheum Dis, 2016, 75(6):1236-45.
[9] Schroder K, Tschopp J.The inflammasomes[J].Cell, 2010, 140(6): 821-32.
[10] Mangan M S J, Olhava E J, Roush W R, et al.Targeting the NLRP3 inflammasome in inflammatory diseases[J].Nat Rev Drug Discov, 2018, 17(8): 588-606.
[11] Indramohan M, Stehlik C, Dorfleutner A.COPs and POPs patrol inflammasome activation[J].J Mol Bio, 2018, 430(2): 153-73.
[12] Pedraza-Alva G, Pérez-Martínez L, Valdez-Hernández L, et al.Negative regulation of the inflammasome: keeping inflammation under control[J].Immunol Rev, 2015, 265(1): 231-57.
[13] Ratsimandresy R A, Chu L H, Khare S, et al.The PYRIN domain-only protein POP2 inhibits inflammasome priming and activation[J].Nat Commun, 2017, 8: 15556.
[14] Lamkanfi M, Dixit V M.A new lead to NLRP3 inhibition[J].J Exp Med, 2017, 214(11):3147-49.
[15] Jiang H, He H, Chen Y, et al.Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders[J].J Exp Med, 2017, 214(11):3219-38.
[16] Qadri M, Jay G D, Zhang L X, et al.Recombinant human proteoglycan-4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of cytokines and chemokines in human and murine macrophages[J].Arthritis Res Ther, 2018, 20(1):192.
[17] Luo L, Wall A A, Tong S J, et al.TLR crosstalk activates LRP1 to recruit Rab8a and PI3Kγ for suppression of inflammatory responses[J].Cell Rep, 2018, 24(11): 3033-44.
[18] Carlsson E, Ding J L, Byrne B.SARM modulates MyD88-mediated TLR activation through BB-loop dependent TIR-TIR interactions[J].Bba-mol Cell Res, 2016, 1863(2): 244-53.
[19] Yong Y H, Wang P, Jia R M, et al.SOCS3 control the activity of NF-κB induced by HSP70 via degradation of MyD88-adapter-like protein(Mal)in IPEC-J2 cells[J].Int J Hyper thermia, 2018,36(1):151-9.
[20] Thueringer J T, Doll N K, Gertner E.Anakinra for the treatment of acute severe gout in critically ill patients[J].Semin Arthritis Rheu, 2015, 45(1):81-5.
[21] Zeng M, Dang W, Chen B, et al.IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response[J].Clin Rheumatol, 2016, 35(9): 2251-8.
[22] Chen Y H, Hsieh S C, Chen W Y, et al.Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3[J].Ann Rheum Dis, 2011, 70(9):1655-63.
[23] Yoshimura A, Ito M, Chikuma S, et al.Negative regulation of cytokine signaling in immunity[J].Cold Spring Harb Perspect Biol, 2018,10(7):a028571.
[24] Malemud C.Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis[J].Int J Mol Sci, 2017, 18(3): 484-93.
[25] 张玲玲, 魏 伟.治疗自身免疫病药物研究进展[J].中国药理学通报,2019, 35(2): 149-56.
[25] Zhang L L, Wei W.Advance in drug treatment of autoimmune diseases[J].Chin Pharmacol Bull, 2019, 35(2): 149-56.
[26] Schauer C, Janko C, Munoz L E, et al.Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines[J].Nat Med, 2014, 20(5): 511-7.
[27] Maueröder C, Kienhöfer D, Hahn J, et al.How neutrophil extracellular traps orchestrate the local immune response in gout[J].J Mol Med(Berl), 2015, 93(7):727-34.
[28] Hilhorst M, Shirai T, Berry G, et al.T cell-macrophage interactions and granuloma formation in vasculitis[J].Front Immunol, 2014, 5:432.
[29] Li Y H, Cao X, Zhao Y, et al.Neutrophil Extracellular Traps formation and aggregation orchestrate induction and resolution of sterile crystal-mediated inflammation[J].Front Immunol, 2018, 9: 1559.
[30] Dalbeth N, Pool B, Gamble G D, et al.Cellular characterization of the gouty tophus: a quantitative analysis[J].Arthritis & Rheumatism, 2014, 62(5):1549-56.


 HUANG Jing-qun,ZHUMiao-zhang,WANG Si-wang.Effects ofG enistein,Apigenin,Quercetin,Rutin and Astilbin on xanthine oxidase activities and serum uric acid levels in hyperuricem ic m ice [J].Chinese Pharmacological Bulletin,2011,(10):561.
 TU Xian kun,YANG Wei zhong,SHI Song sheng,et al.Inhibitory effect of baicalin on the expression of TNFα and AQP4 and the brain damage following cerebral ischemia in rats[J].Chinese Pharmacological Bulletin,2013,(10):1222.
[4]项 琪,付 欣,冉丕鑫,等. 地塞米松及N-乙酰半胱氨酸抑制A549细胞IL-8及ICAM-1表达的机制研究[J].中国药理学通报,2014,(09):1293.
 XIANG Qi,FU Xin,RAN Pi-xin,et al. Study of mechanism of DXM and NAC inhibiting expression of IL-8 and ICAM-1 in A549 cells[J].Chinese Pharmacological Bulletin,2014,(10):1293.
[5]王涛丽,顾 兵,李华南,等.急性脊髓损伤后的炎症反应及其抗炎治疗[J].中国药理学通报,2015,(04):452.
 WANG Tao-li,GU Bing,LI Hua-nan,et al.Inflammatory response and anti-inflammatory therapy after acute spinal cord injury[J].Chinese Pharmacological Bulletin,2015,(10):452.
[6]刘理静,钱 红,尹辉明,等.IL-17单克隆抗体对肺纤维化大鼠的保护作用及部分机制研究[J].中国药理学通报,2015,(11):1586.[doi:10.3969/j.issn.1001-1978.2015.11.021]
 LIU Li-jing,QIAN Hong,YIN Hui-ming,et al.Protective effect of IL-17 monoclonal antibody on rats with pulmonary fibrosis and its partial mechanisms[J].Chinese Pharmacological Bulletin,2015,(10):1586.[doi:10.3969/j.issn.1001-1978.2015.11.021]
[7]匡胜男,罗 映,田小燕,等.美洛昔康改善慢性应激大鼠抑郁行为的机制初探[J].中国药理学通报,2016,(02):263.[doi:10.3969/j.issn.1001-1978.2016.02.022]
 KUANG Sheng-nan,LUO Ying,TIAN Xiao-yan,et al.Effect of meloxicam on CUMS-induced depressive-like behavior in ratsand its preliminary mechanism[J].Chinese Pharmacological Bulletin,2016,(10):263.[doi:10.3969/j.issn.1001-1978.2016.02.022]
[8]万 强,杨玉萍,刘中勇.大蒜素对PM2.5损伤EA.hy926内皮细胞的保护作用及机制[J].中国药理学通报,2016,(05):692.[doi:10.3969/j.issn.1001-1978.2016.05.019]
 WAN Qiang,YANG Yu-ping,LIU Zhong-yong.Allicin prevents EA.hy926 endothelial cell injury induced by PM2.5 via inhibiting ERK1/2 pathway[J].Chinese Pharmacological Bulletin,2016,(10):692.[doi:10.3969/j.issn.1001-1978.2016.05.019]
 BIAN Mian-li,CHEN Xing-ran,et al.Study on mechanism of NOXs in liver fibrosis[J].Chinese Pharmacological Bulletin,2016,(10):1490.[doi:10.3969/j.issn.1001-1978.2016.11.003]
[10]周 英,李 敏,孙黔云.绿原酸、咖啡酸和阿魏酸对补体旁路激活致内皮细胞炎症相关分子表达的干预[J].中国药理学通报,2016,(12):1723.[doi:10.3969/j.issn.1001-1978.2016.12.017]
 ZHOU Ying,Li Min,SUN Qian-yun.Effect of chlorogenic acid, caffeic acid, and ferulic acid on inhibition of inflammatory response of HMECs induced by activated complement alternative pathway[J].Chinese Pharmacological Bulletin,2016,(10):1723.[doi:10.3969/j.issn.1001-1978.2016.12.017]


收稿日期:2019-06-18,修回日期:2019-07-20 基金项目:国家自然科学基金资助项目(No 81860857); 国家中医药管理局第四批全国中医(临床、基础)优秀人才研修项目[国中医药人教发(2017)24号]; 江西省卫生和计划生育委员会中医药科研基金项目(No 2016A077,2017Z010) 作者简介:陈玉年(1995-),女,硕士生,研究方向:免疫药理学,E-mail:cyunian@163.com; 李华南(1974-),女,博士,副教授,主任中医师,研究方向:痛风的现代中医药诊治,通讯作者,E-mail: bguemory@hotmail.com
更新日期/Last Update: 2019-09-15